Log in

Beam Therapeutics Stock Forecast, Price & News

+2.38 (+6.70 %)
(As of 10/23/2020 12:00 AM ET)
Today's Range
Now: $37.89
50-Day Range
MA: $27.20
52-Week Range
Now: $37.89
Volume1.12 million shs
Average Volume620,133 shs
Market Capitalization$1.96 billion
P/E RatioN/A
Dividend YieldN/A
Beam Therapeutics Inc., a biotechnology company, engages in developing precision genetic medicines for patients suffering from serious diseases in the United States. It is developing therapies for the development of sickle cell disease and beta-thalassemia; CAR-T cell therapies for pediatric T-cell acute lymphoblastic leukemia and pediatric acute myeloid leukemia; therapies for alpha-1 antitrypsin deficiency and glycogen storage disorder 1A; and therapies for ocular and central nervous system disorders. The company was founded in 2017 and is based in Cambridge, Massachusetts.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 1.5Community Rank: 1.9Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.01 out of 5 stars

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Current SymbolNASDAQ:BEAM



Sales & Book Value

Annual Sales$20,000.00
Price / Sales98,002.49



Market Cap$1.96 billion
Next Earnings Date11/11/2020 (Estimated)
OptionableNot Optionable
+2.38 (+6.70 %)
(As of 10/23/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive BEAM News and Ratings via Email

Sign-up to receive the latest news and ratings for BEAM and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Beam Therapeutics (NASDAQ:BEAM) Frequently Asked Questions

How has Beam Therapeutics' stock price been impacted by COVID-19?

Beam Therapeutics' stock was trading at $21.25 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, BEAM stock has increased by 78.3% and is now trading at $37.89.
View which stocks have been most impacted by COVID-19

Do Wall Street analysts recommend investors buy shares of Beam Therapeutics?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Beam Therapeutics in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Beam Therapeutics

When is Beam Therapeutics' next earnings date?

Beam Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, November 11th 2020.
View our earnings forecast for Beam Therapeutics

How were Beam Therapeutics' earnings last quarter?

Beam Therapeutics Inc (NASDAQ:BEAM) announced its quarterly earnings results on Wednesday, August, 12th. The company reported ($0.69) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.56) by $0.13. The company had revenue of $0.01 million for the quarter, compared to the consensus estimate of $0.01 million.
View Beam Therapeutics' earnings history

What price target have analysts set for BEAM?

2 analysts have issued 12-month price targets for Beam Therapeutics' stock. Their forecasts range from $33.00 to $33.00. On average, they anticipate Beam Therapeutics' share price to reach $33.00 in the next year. This suggests that the stock has a possible downside of 12.9%.
View analysts' price targets for Beam Therapeutics

Who are some of Beam Therapeutics' key competitors?

What other stocks do shareholders of Beam Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Beam Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Editas Medicine (EDIT), Cisco Systems (CSCO), Square (SQ), Skyworks Solutions (SWKS), Akoustis Technologies (AKTS), InVitae (NVTA), QUALCOMM (QCOM) and Alector (ALEC).

When did Beam Therapeutics IPO?

(BEAM) raised $101 million in an IPO on Thursday, February 6th 2020. The company issued 6,300,000 shares at $15.00-$17.00 per share. J.P. Morgan, Jefferies and Barclays acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.

What is Beam Therapeutics' stock symbol?

Beam Therapeutics trades on the NASDAQ under the ticker symbol "BEAM."

How do I buy shares of Beam Therapeutics?

Shares of BEAM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Beam Therapeutics' stock price today?

One share of BEAM stock can currently be purchased for approximately $37.89.

How big of a company is Beam Therapeutics?

Beam Therapeutics has a market capitalization of $1.96 billion and generates $20,000.00 in revenue each year. The company earns $-78,330,000.00 in net income (profit) each year or ($14.05) on an earnings per share basis.

What is Beam Therapeutics' official website?

The official website for Beam Therapeutics is www.beamtx.com.

How can I contact Beam Therapeutics?

Beam Therapeutics' mailing address is 26 LANDSDOWNE STREET, CAMBRIDGE MA, 02139. The company can be reached via phone at 857-327-8775 or via email at [email protected]

This page was last updated on 10/24/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.